Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

NCT ID: NCT06170710

Last Updated: 2023-12-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 173 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-01
• Study Completion Date: 2027-11-30

Brief Summary

This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).

Detailed Description

This open-label, randomized, controlled, phase II study will include 173 patients who have been operated for their LA SCCHN with high risk.

Subjects will be randomized (1:1) to receive post-operative concomitant cisplatin-RT followed by/not PD-1 antibody.

The study is designed with the general objective of demonstrating that treatment CCRT followed by PD-1 antibody is more efficient than CCRT alone.

Conditions

Head and Neck Squamous Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RT+ cisplatin+Anti-PD-1 antibody

Concurrent cisplatin-RT followed by PD-1 antibody

Group Type: EXPERIMENTAL

Anti-PD-1 monoclonal antibody

Intervention Type: DRUG

Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:

Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W

Postoperative CCRT

Intervention Type: OTHER

Postoperative chemoradiotherapy

RT+ cisplatin

Concurrent cisplatin-RT

Group Type: ACTIVE_COMPARATOR

Postoperative CCRT

Intervention Type: OTHER

Postoperative chemoradiotherapy

Interventions

Anti-PD-1 monoclonal antibody

Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:

Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W

Intervention Type: DRUG

Postoperative CCRT

Postoperative chemoradiotherapy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Histologically proven squamous cell carcinoma of the head and neck which include but not limit following primary sites: oral cavity, oropharynx, hypopharynx or larynx
• Patients eligible with one or more High-Risk factors of the following: For HPV+ OPSCC: T4 OR cN3 OR pN2 OR non-R0 resection OR resection margin<5mm OR ENE (+) OR perineural invasion OR vessel/lymphatic vessel invasion；For HPV- HNSCC：T4 OR cN3 OR pN2 OR non-R0 resection OR resection margin<5mm OR ENE (+) OR perineural invasion OR vessel/lymphatic vessel invasion OR IV/V cervical lymph node metastases
• ECOG performance score 0-1
• PD-L1 expression with CPS>1
• No contraindications to immunotherapy or chemoradiotherapy
• Adequate organ function
• Female subject of childbearing potential should have a negative pregnancy test within 7 days prior to receiving the first dose of study medication.Female subjects of childbearing potential must be willing to use an adequate method of contraception during the course of the study and 60 days after the last dose of study medication.
• Reproductive male subjects must agree to use an adequate method of contraception during the course of the study and 60 days after the last dose of study medication.
• Informed consent is obtainable.

Exclusion Criteria

• Previous or co-existing malignancies, except cured basal cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer
• Active infection
• Known active viral infection Human Immunodeficiency Virus (HIV), Hepatitis B/C) or known history of positive test for HIV
• Active and/or historical autoimmune disease, except patients with vitiligo or asthma that has completely resolved in childhood and does not require any intervention in adulthood
• Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication
• Pregnant, breastfeeding patients, and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in the protocol for the duration of the study
• History of PD-1/L1 treatment
• If the subjects underwent major surgery for non-tumors, the toxicity and complications of the surgery needed to be adequately treated and the body conditions returned to normal
• Concurrent enrollment in another clinical trial using an investigational anti-cancer treatment within 28 days prior to the first dose of study treatment
• Other circumstances leading to the termination of the study, as determined by the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jingbo Wang, Dr.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Cencer/Cancer hospital

Locations

National Cancer Cencer/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jingbo Wang, Dr.

Role: CONTACT

Phone: +861087787249

Email: wangjingbo201001@163.com

Facility Contacts

Jingbo Wang, Dr.

Role: primary

Other Identifiers

23/219-3961

Identifier Type: -

Identifier Source: org_study_id